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ABSTRACT
Osteoarthritic chondrocytes secrete matrix metalloproteinase-13 (MMP-13) in response to interleukin-1
(IL-1), causing digestion of type II collagen in cartilage. Using chondrocytic cells, we previously
determined that IL-1 induced a strong MMP-13
transcriptional response that requires p38 MAPK,
JNK and the transcription factor NF-κB. Now, we
have studied the tissue-specific transcriptional
regulation of MMP-13. Constitutive expression of the
transcription factor Runx-2 correlated with the ability
of a cell type to express MMP-13 and was required for
IL-1 induction; moreover, Runx-2 enhanced IL-1
induction of MMP-13 transcription by synergizing
with the p38 MAPK signaling pathway. Transiently
transfected MMP-13 promoters were not IL-1 inducible.
However, –405 bp of stably integrated promoter was
sufficient for 5- to 6-fold IL-1 induction of reporter
activity and this integrated reporter required the
same p38 MAPK pathway as the endogenous gene.
Finally, mutation of the proximal Runx binding site
and the proximal AP-1 site blunted the transcriptional response to IL-1, and double mutation
synergistically decreased reporter activity. In
summary, our data suggest that the transcriptional
MMP-13 response to IL-1 is controlled by the p38
pathway interacting at the MMP-13 promoter through
the tissue-specific transcription factor Runx-2 and
the ubiquitous AP-1 transcription factor.
INTRODUCTION
The matrix metalloproteinases (MMPs) are a family of
enzymes that collectively degrade the components of the extracellular matrix. MMPs have crucial roles in normal physiological
processes such as development and wound healing, where
expression of these enzymes is typically low. In contrast,
aberrant MMP expression occurs in several disease states,
including atherosclerosis, tumor invasion and arthritic diseases
(1,2). MMPs mediate irreversible matrix degradation and

subsequent joint destruction in rheumatoid arthritis and
osteoarthritis (OA). Irreversible degradation of type II collagen
is a critical early event in the pathogenesis of OA (3) and MMP
expression is restricted to active OA cartilage lesions, where
destruction occurs. A subset of MMPs, the collagenases
(MMP-1, MMP-8, MMP-13 and MMP-14), are the only
enzymes that perform the initial cleavage of triple helical
collagen and, thus, they are the rate-limiting step for collagen
degradation in OA.
OA chondrocytes express MMP-13 and this MMP cleaves
type II collagen more efficiently than MMP-1 and MMP-8 (4).
Moreover, MMP-13 expression co-localizes with type II
collagen degradation in active OA lesions, implying that the
enzyme plays a pivotal role in cartilage degradation in this
disease (4). Additionally, inhibition of MMP-13 in cartilage
explant models greatly reduced type II collagen destruction
and overexpression of MMP-13 by articular chondrocytes in a
transgenic mouse model resulted in cartilage destruction that
strongly resembled OA (5). MMP-13 is, therefore, believed to
mediate type II collagen degradation in OA.
The expression of MMP-13 is more restricted than the other
secreted collagenase, MMP-1. Normally, MMP-13 expression
by chondrocytes appears to be limited to development;
chondrocytes produce MMP-13 to remove type II collagen at
the growth plate during bone formation (6,7). In OA, autocrine
secretion of the inflammatory cytokine interleukin-1 (IL-1) by
chondrocytes stimulates MMP-13 expression and cartilage
degradation in the absence of inflammatory cells (3,4,8). We
recently demonstrated that IL-1 induction of MMP-13 gene
expression in chondrocytes required the transcription factor
NF-κB as well as p38 MAPK and JNK, but not ERK MAPK
(9). JNK was recently shown to be required for IL-1 induction
of MMP-13 expression in mouse fibroblasts and a rheumatoid
arthritis model (10). IL-1-activated MAPK/JNK pathways
affect numerous regulatory processes, including the synthesis
and activity of the AP-1 transcription factor composed of Fos/Jun
heterodimers and Jun/Jun homodimers (11). A proximal AP-1
site is found in the MMP-13 promoter and in the promoter of
many inducible genes, including numerous MMPs (12).
Coupled with our previous work studying signaling pathways,
this observation suggests that AP-1 is involved in the regulation of MMP-13 transcription by IL-1, but that it alone is not
responsible for tissue-specific expression of MMP-13.
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Figure 1. Homology alignment of the proximal MMP-13 promoters from mouse, rabbit and human sequence. The numbering is based on the start of transcription
mapped in IL-1-treated OA chondrocytes (36). Conserved AP-1, Runx and Ets sites are in bold; the arrow denotes the human transcriptional start site. The translational start site is highlighted in bold from nucleotide +22 to +24. Alignment was made using GeneInspector (Textco Inc.)

First, to explore the tissue-specific expression of MMP-13,
we examined the functional role of a potential Runx proteinbinding site 138 bp upstream of the transcriptional start site
(Fig. 1) that is not found in other MMP promoters. The Runx
site binds proteins from the Runx family, including Runx-2
(Cbfa1), an essential transcription factor for osteoblast and
chondrocyte development (13–16). Runx-2 forms a
heterodimeric complex with its partner Cbf-β; Runx-2 binds
DNA directly while Cbf-β modulates the affinity of the
complex for DNA (17). We found that constitutive Runx-2
expression correlated with the ability of a cell to produce
MMP-13 in response to IL-1. Moreover, we determined that
Runx-2 in cooperation with AP-1 was required for IL-1 induction of MMP-13 and that Runx-2 activity was modulated by
IL-1-induced p38 MAPK activation. Second, we found that
stable integration of the proximal 405 bp of the MMP-13
promoter was necessary for IL-1 induction of transcription,
implying that chromatin structure may be important for transcriptional regulation.
MATERIALS AND METHODS
Cell culture
SW-1353 cells were obtained from the American Type Culture
Collection and cells were grown in 150 mm diameter culture

dishes in DMEM containing 10% fetal calf serum (FCS) and
penicillin/streptomycin (37°C in 5% CO2) (Life Technologies,
Rockville, MD). Cells were passaged 1:4 with 0.25% trypsin.
For most experiments, cells were grown to confluence in 35 mm
6-well plates, washed with Hanks’ balanced salt solution
(HBSS) to remove traces of serum and placed in 2 ml of serumfree DMEM with 0.2% lactalbumin hydrosylate (DMEM/LH),
with or without 10 ng/ml IL-1β (92 U/ng; Promega, Madison,
WI).
Western blots
One milliliter of serum-free medium from each well of 6-well
cultures was TCA precipitated and analyzed by SDS–PAGE
and western immunoblotting as described previously (18).
Briefly, 10% SDS–PAGE gels were run and proteins were
transferred to Immobilon PVDF membranes (Millipore,
Bedford, MA). Supernatants from transfection experiments
were assayed for MMP-1 and MMP-13 protein. MMP-13 antibody was graciously provided by Peter Mitchell (Pfizer) (18).
Anti-MMP-1 polyclonal antibody was purchased from
Chemicon (Temecula, CA). Anti-Runx2 antibody was
graciously provided by Gerard Karsenty (Baylor School of
Medicine) (15). Peroxidase-conjugated secondary antibodies
and enhanced chemiluminesence (Amersham, Piscataway, NJ)
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Figure 2. Runx-2 expression correlates with IL-1 inducibility of MMP-13.
Total RNA was harvested from SW-1353 cells, rabbit fibroblasts or human
foreskin fibroblasts after treatment for the times indicated. Aliquots of 10 µg
were analyzed by northern blot analysis using a 32P-labelled probe from the
3 ′-end of the mouse Runx-2 cDNA. rRNA is shown as a loading control. Band
intensities were compared with NIH Image software.

were used to visualize bound primary antibodies. NIH Image
software was used to compare band intensities.
Northern blots
Total RNA was isolated using the Trizol protocol (Life Technologies) and was subjected to northern blot analysis. Briefly,
10 µg RNA was loaded on a 1% agarose–formaldehyde–
formamide gel, electrophoresed and blotted to GeneScreen
membrane (NEN, Boston, MA). RNA was then UV
crosslinked and probed with a 1017 bp SstI–EcoRI fragment of
mouse Runx2 cDNA that was random hexamer labeled with
[α-32P]dCTP and visualized by autoradiography.
Reporter constructs
All MMP-13 promoter constructs were cloned into the luciferase reporter vector pGL3 Basic (Promega). The 3.4 and 1.6 kb
constructs were obtained by rapid amplification of genomic
DNA ends; smaller constructs were created by PCR cloning
utilizing the SstI and KpnI sites of pGL3 basic. A segment of
8.0 kb of 5′-flanking DNA was provided by Karen Hasty
(University of Tennessee Medical School). Mutations to the
proximal AP-1- and Runx-binding sites were made using overlapping PCR (19). The proximal AP-1 site was changed from
TGACTCA to ACTCTCA. The proximal Runx-binding site
was changed from AACCACA to ACTAACA. The sequence
of all promoter constructs was verified by DNA sequencing.
The runt domain of Runx-2 was cloned into pCMVTag5A
(Stratagene, La Jolla, CA) using PCR. An expression plasmid
containing the mouse Runx-2 isoform starting with the amino
acids MASN was provided by Gerard Karsenty (Baylor
University Medical School) (15). The MKK3 plasmid was
provided by Roger Davis (University of Massachusetts
Medical School). The ∆MEKK1 plasmid was obtained from
Stratagene. The pyridinyl imidazole p38 inhibitor SB203580 and
the MEK inhibitor PD98059 were purchased from CalBiochem
(San Diego, CA).

Figure 3. Runt domain expression specifically inhibits IL-1 induction of
endogenous MMP-13. Samples of 3 × 105 SW-1353 cells were transfected with
1 µg empty pCMV-Tag5A expression plasmid, a CMV driven Runx-2 expression plasmid or pCMV-Tag5A-runt using 10 µl/well Geneporter reagent. After
overnight recovery, cells were treated for 24 h with 2 ml of serum-free DMEM/
LH or LH and 10 ng/ml IL-1β. Next, 1 ml of supernatant was TCA precipitated
and analyzed by SDS–PAGE and western blotting. Polyclonal antibodies to
either MMP-13 or MMP-1 were used to visualize protein. Band intensities
were compared with NIH Image. A transfection efficiency of 50% was measured by transfection of the green fluorescent protein-expressing vector pEGFP
and fluorescence microscopy (9).

Transient transfections
All experiments were performed in triplicate. SW-1353 cells
were plated at a density of 2 × 105 per well in 6-well tissue
culture plates. The following morning 1 µg total DNA plus 10 µl
of Geneporter-1 (Gene Therapy Systems, San Diego, CA)
reagent in 1 ml of serum-free medium were added for 4 h. One
milliliter of 20% FCS DMEM was then added for overnight
incubation. The next day, the experimental treatments were
added for the times indicated. Cells were then washed three
times with ice-cold phosphate-buffered saline and lysed in
25 mM glycylglycine, 4 mM EGTA, 15 mM MgSO4, 1%
Triton X-100 and 1 mM DTT. Luciferase activity was measured
in a Dynatech ML2250 luminometer and reported as relative
light units (RLU).
For analysis of expression of the endogenous MMP-13 gene,
SW-1353 cells were plated at 3 × 105 cells/well in 6-well plates
and cultured overnight in 10% FCS DMEM. The following
day, 1 µg total DNA plus 10 µl of Geneporter-1 per well was
incubated with the cells for 5 h in 1 ml of serum-free medium
(LH), followed by addition of 1 ml of DMEM containing 20%
FCS for overnight incubation at 37°C. The following day cells
were washed three times with HBSS, and then 2 ml of DMEM/
LH with or without 10 ng/ml IL-1β was added. For
western blot analysis, after 24 h 1 ml of supernatant was
TCA precipitated and analyzed by SDS–PAGE and immunoblotting.
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Stable cell lines
For each construct, a 90 mm plate of SW-1353 cells that were
70% confluent was co-transfected with 2.3 µg of the
neomycin-expressing vector pCMV-Tag5A (Stratagene) and
2.3 µg of the corresponding pGL3-promoter construct using
46.7 µl/plate Geneporter. Two days after transfection, cells
were passaged into a 150 mm plate containing 800 µg/ml G418
(Stratagene) in 10% FCS. Cells were passaged once a week for
3 weeks, when single colonies were isolated by serial dilution
in 96-well plates. Cells were selected for 8 weeks in G418
before experiments were begun. Stable cell lines were maintained by selection in 800 µg/ml G418. To create pooled stable
lines, cells were transfected as above and plates containing
several thousand colonies were passaged once a week in
800 µg/ml G418 for 4 weeks before analysis.
RESULTS
Constitutive Runx-2 expression correlates with MMP-13
production
Previously, we determined that the SW-1353 human chondrosarcoma cell line provides an appropriate model for studying
the signaling pathways used by primary chondrocytes to
produce MMP-13 transcript in response to IL-1 (9). We
demonstrated that IL-1 strongly induces MMP-13 transcription
in the SW-1353 line by 2 h via the p38 MAPK, JNK and NF-κB
inflammatory signaling pathways (9). Because the MMP-13
promoter contains a Runx-binding site (Fig. 1), and because
Runx-2 is involved in cartilage and bone development (13–16),
we hypothesized that the transcription factor Runx-2 is
involved in IL-1 induction of MMP-13. Therefore, the expression of Runx-2 mRNA was compared among human foreskin
fibroblasts (HFFs), rabbit synovial fibroblasts (RFs) and the
chondrosarcoma cell line SW-1353. A time course experiment
showed that Runx-2 was constitutively present in SW-1353
cells treated with serum-free medium up to 24 h (Fig. 2), but
that Runx-2 was not expressed in HFFs or RFs, cells that make
no to low levels of MMP-13 in response to IL-1, respectively
(18). Further, IL-1 slightly increased Runx-2 message in SW1353 cells up to 2-fold at 4 and 24 h. Western blot analysis of
HFF and SW-1353 nuclear extracts verified the results of
northern blots (data not shown). These experiments demonstrate that Runx-2 expression correlates with MMP-13 production and that mRNA and protein levels of Runx-2 are
constitutively high in the nucleus of SW-1353 cells.
IL-1 induction of endogenous MMP-13 requires Runx-2
The Runx proteins bind to DNA via the runt domain, a
conserved domain found in the middle of the polypeptide.

Expression of the Runx-2 runt domain acts as an inhibitor of
transactivation (20,21), since the overexpressed runt domain
binds to its binding site more tightly than the wild-type protein
and is transactivation deficient (20). In order to test the hypothesis that Runx-2 contributes to IL-1 induction of MMP-13,
SW-1353 cells were transfected with CMV-driven expression
plasmids containing either wild-type Runx-2 or the runt
domain. Twenty-four hours after transfection, cells were
placed in serum-free medium with or without IL-1 for 24 h and
supernatants were analyzed by western blotting. As expected,
untreated cells produced undetectable levels of MMP-13 and
MMP-1 and treatment with IL-1 resulted in substantial production of both proteins (9; Fig. 3). We also found that overexpression of the runt domain inhibited IL-1 induction of MMP-13 by
∼50%, which parallels the transfection efficiency (see below).
In contrast, transfection with wild-type Runx-2 increased
MMP-13 induction by ∼2-fold. To analyze the specificity of
the effect of Runx-2, MMP-1 levels were assayed from the
same experiment and they were unaffected by transfection of
either construct (Fig. 3). Transfection efficiency was estimated
to be ∼50% by transfection of a GFP expression plasmid (9; data
not shown). These experiments demonstrate that Runx-2
contributes to expression of the endogenous MMP-13 gene by
IL-1, but not to induction of MMP-1. Further, the contribution
of Runx-2 to gene expression correlates with the presence of a
Runx-2 site in the MMP-13 promoter.

∆MEKK1 and MKK3 synergize with Runx-2 to activate
405 bp of MMP-13 promoter
DNA sequence analysis of the proximal promoter demonstrated that the first 370 bp of MMP-13 5′-flanking DNA are
highly conserved among mouse, rabbit and human (Fig. 1).
This sequence contains a putative AP-1 site, an ETS-binding
site and a Runx-binding site (Fig. 1). Initially, we used gel
mobility shift assays (22) to determine whether IL-1 induced
changes in the pattern of proteins binding to the AP-1 and
Runx-2 sites. We found high constitutive binding and no
significant changes after IL-1 treatment (data not shown).
Therefore, we hypothesized that the AP-1 and Runx-2 proteins
are constitutively bound and the effect of IL-1 on MMP-13
gene expression may occur through kinase-mediated phosphorylation of these target transcription factors, rather than
through an increase in their synthesis. A recent study demonstrated that ERK MAPK can phosphorylate Runx-2 and that
phosphorylation increases the ability of the protein to transactivate the osteocalcin promoter (23). Since we have demonstrated that IL-1 activation of p38 MAPK and JNK was
necessary for induction of MMP-13 (9), we postulated that p38
MAPK and/or JNK may phosphorylate Runx-2 and that

Figure 4. (Opposite) ∆MEKK1 and MKK3 synergistically activate 405 bp of MMP-13 reporter through Runx-2. Samples of 2 × 105 SW-1353 cells were transfected with
500 ng of the proximal 405 bp of MMP-13 (A), of 5′-flanking DNA (B) or 4.3 kb of MMP-1 promoter (C), linked to the luciferase reporter gene in pGL3. Cells
were co-transfected with 500 ng total of expression plasmid containing combinations of cDNAs for Runx-2, constitutively active ∆MEKK1 (Stratagene) or constitutively active MKK3 (26) driven by a CMV promoter. Total DNA was kept constant by addition of the empty pCMVTag5A expression plasmid. Aliquots of
10 µl of Geneporter (Gene Therapy Systems) were used to transfect the cells. Twenty-four hours after transfection, cells were placed in serum-free medium for 24 h or in
10 µM SB203580, cell extracts were made and assayed for luciferase activity. Units shown are relative light units (RLU). Individual treatments were performed in triplicate;
error bars represent standard deviations. Values indicate fold induction over basal activity of the 405 bp construct.
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phosphorylation is involved in transcriptional activation of the
MMP-13 promoter.
Previous studies have shown that when MMP-13 promoter
constructs and Runx-2 are co-transfected into HeLa cells (cells
that do not express Runx-2 or MMP-13), Runx-2 could drive
MMP-13 reporter activity (24). Therefore, we transiently cotransfected SW-1353 cells with 405 bp of MMP-13 promoter
in the pGL3 luciferase reporter along with expression
constructs of Runx-2 and upstream activators of MAPK pathways, such as ∆MEKK1, a constitutively active MAPK kinase
that activates JNK, p38 and ERK (25). Transfection of Runx-2
alone induced reporter activity 2-fold, while ∆MEKK1 alone
induced the promoter–reporter to a similar extent (1.7-fold)
(Fig. 4A). However, when ∆MEKK1 and Runx-2 were cotransfected with the reporter gene, a synergistic 19-fold
increase in reporter activity occurred. Another upstream
MAPK activator is MKK3, a MAPK kinase that phosphorylates and activates p38 MAPK, which is a kinase
required for MMP-13 transcription (26). Transfection of
constitutively active MKK3 alone did not increase reporter
activity. Combined with Runx-2, MKK3 synergistically
induced transcription 10-fold. Transfection of the empty pGL3
vector resulted in extremely low reporter expression that was
not affected by Runx-2 co-transfection (data not shown). This
synergism between Runx-2 and the p38 MAPK activator
suggests direct integration between MAPK signaling and
Runx-2 binding at the promoter of MMP-13.
SB203580 inhibits MKK3 Runx-2 synergism
Because MKK3 activates p38 MAPK, the synergism seen with
Runx-2 should be sensitive to treatment with the p38 inhibitor
SB203580, an inhibitor that blocks IL-1 induction of the
endogenous MMP-13 gene (9). Therefore, cells were transiently co-transfected with 405 bp of MMP-13 promoter along
with expression constructs for Runx-2 and MKK3 (Fig. 4B).
As in the previous experiment, Runx-2 and MKK3 alone gave
a modest increase in transcription, while together the increase
was synergistic. Addition of the p38 inhibitor reduced the
synergistic induction mediated by MKK3 and Runx-2 from
6.4- to 3.4-fold over the control. In summary, MKK3–Runx-2
synergism through 405 bp of the MMP-13 promoter is inhibited
by a p38 MAPK inhibitor, demonstrating that, like the endogenous MMP-13 gene, active p38 MAPK is required for the
effect.
Runx-2 activation and synergism is specific for MMP-13
Because MMP-1 does not contain a Runx-2-binding sequence
in its promoter, but does contain AP-1 sites that respond to the
MAPK/JNK pathways (27), as a control we investigated the
ability of Runx-2 to synergistically transactivate the MMP-1
promoter with expression constructs for MAPK and JNK activators (Fig. 4C). When a 4.3 kb piece of MMP-1 promoter
DNA that is responsive to IL-1 (28) was transiently transfected
into SW-1353 cells along with Runx-2, there was no effect on
reporter activity. In contrast to the MMP-13 promoter, MKK3
and ∆MEKK1 each activated transcription of the MMP-1
reporter, but co-transfection of these expression plasmids and
Runx-2 did not increase transcription further. This experiment
demonstrates the specificity of p38 MAPK–Runx-2 synergism
for the MMP-13 promoter and suggests that the Runx-binding
site is needed for IL-1 induction of MMP-13.

IL-1 does not stimulate transiently transfected MMP-13
promoter–reporter constructs
Next, we focused on defining the cis-acting sequences required
for regulation of MMP-13 transcription by IL-1 by generating
a series of MMP-13 5′-flanking constructs in the luciferase
reporter vector pGL3 basic (Fig. 5A). When constructs from
–181 bp to –8 kb were transiently transfected into SW-1353
cells, treatment with IL-1 resulted either in no effect or repression of luciferase activity, in contrast to the endogenous gene,
which shows a strong transcriptional induction (9; Fig. 5B and
data not shown). We saw the same results when we used a βgalactosidase reporter vector or when other cell lines and
primary cells that produce MMP-13 were transfected. In
contrast, a pGL3-MMP-1 promoter construct (28) was IL-1
inducible (Fig. 5C) and a NF-κB site-driven luciferase reporter
was 4.8-fold increased after IL-1 treatment (data not shown).
In summary, we were unable to detect IL-1 regulatory regions
in 8.0 kb of MMP-13 5′-flanking DNA and 1.6 kb of 3′flanking DNA by transient transfections. This suggests that
additional cis-acting sequences are required or that integration
of promoter DNA into native chromatin is needed to observe IL-1
regulation of MMP-13 (see below).
IL-1 stimulates MMP-13 promoter–reporter activity in
stable transfectants
To test the hypothesis that integration of the reporter plasmid
into the chromosome was required for appropriate regulation
of the promoter by IL-1, stable transfectants were created by
co-transfecting pGL3 reporter constructs containing either 8.0 kb
or 405 bp of MMP-13 5′-flanking DNA with pCMVTag5, a
neomycin expression vector (see Materials and Methods).
Three of five clones containing 405 bp and one of five clones
containing 8.0 kb expressed the luciferase reporter and were
IL-1 inducible (Fig. 6A and data not shown). All luciferasepositive clones demonstrated a similar fold induction after IL-1
treatment, suggesting that proximal sequences control transcription and that the sequence between –8.0 kb and –405 bp is
not necessary. Additionally, control lines created by stable
transfection with the empty pGL3 vector did not basally
express luciferase and were not IL-1 inducible, demonstrating
that the IL-1-responsive sequences are not found in the vector
DNA (data not shown).
Next, we investigated whether the stably integrated promoter
could be inhibited by the p38 inhibitor SB203580, which
inhibits IL-1 induction of the endogenous gene (9). As noted
above, treatment of the 405(3) clone with IL-1 induced the
luciferase reporter 5.6-fold (Fig. 6A) and concomitant treatment
of the cell line with 10 µM SB203580 reduced IL-1 induction
to 2.1-fold, with no effect on basal activity. Treatment with 40 µM
PD98059 had no effect on basal activity or IL-1 induction, also
consistent with the endogenous gene (9). These data demonstrate that integration of the MMP-13 promoter results in
appropriate reporter gene induction and suggest that integration is required for IL-1 induction of MMP-13. Moreover, the
stably integrated promoter–reporter constructs require p38
MAPK and do not require the MEK/ERK pathway, exactly
like the endogenous MMP-13 gene (9). Thus, these stable cell
lines provide a model system for elucidating the specific
cis-acting sequences required for IL-1 induction of MMP-13.
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Figure 5. (A) pGL3 MMP-13 reporter constructs. The numbering of constructs is based on the start of translation. 5′-Flanking DNA was cloned into pGL3 basic
by PCR (181 and 405 bp constructs) and rapid amplification of genomic DNA ends (RAGE) (1.6 and 3.4 kb constructs). The 8.0 kb 5′-flanking region was subcloned from a pBetaGal construct graciously provided by Karen Hasty (University of Tennessee). (B) Transient transfection of 181 and 405 bp of MMP-13 5′flanking DNA into SW-1353 cells. Samples of 2 × 105 SW-1353 cells were transfected with 1 µg pGL3 luciferase reporter construct containing MMP-13 5′-flanking DNA
using 10 µl of Geneporter. (C) Transient transfection of 4.3 kb of MMP-1 5′-flanking DNA. Samples of 2 × 105 SW-1353 cells were transfected with 1 µg pGL3
luciferase reporter construct containing 4.3 kb of MMP-1 5′-flanking DNA (37). Cells were treated with 10 ng/ml IL-1β for 24 h. In all three experiments,
luciferase activity was assayed in a luminometer and expressed as RLU. Error bars denote standard deviations.
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Figure 6. Stable transfectants of MMP-13 5′-flanking DNA reporter constructs respond to IL-1β. Stably transfected SW-1353 cells containing 405 bp of MMP-13
5′-flanking DNA were created by co-transfecting cells with a reporter construct and the pCMV-Tag5A vector expressing the neomycin resistance gene, followed
by 2 months of selection in G418. To assay the integrated reporter constructs, 2 × 105 cells derived from single cell clones were plated and treated with 10 ng/ml
IL-1β for 24 h. Luciferase activity was assayed and plotted as RLU. (A) The 405 bp stably integrated reporter constructs are inhibited by the same MAPK inhibitors
as the endogenous MMP-13 gene. A 405 bp clone was treated with 10 ng/ml IL-1β for 24 h with and without 40 µM MEK inhibitor PD98059 or 10 µM p38
inhibitor SB203580. Luciferase activity was assayed and plotted as RLU. (B) IL-1 synergizes with Runx-2 in stable transfectants. Samples of 2 × 105 SW-1353
cells stably transfected with 405 bp of MMP-13 promoter DNA were transiently transfected with 1 µg pCMVTag5A or pCMV Runx-2 using 10 µl of Geneporter.
Twenty-four hours after transfection, cells were treated with 10 ng/ml IL-1 for 24 h and/or 10 µM SB203580 in serum-free medium. All treatments were done in
triplicate; cells were harvested and assayed for luciferase activity. Luciferase activity is shown as RLU; error bars represent standard deviations. Values indicate
fold induction over control.

IL-1 and Runx-2 synergize to activate the MMP-13
promoter in stable transfectants
Next, we tested the ability of a stably transfected cell line to
respond to Runx-2 and IL-1. The cells were transiently transfected with an empty vector or with the same vector containing
a Runx-2 construct, with and without IL-1 treatment. In cells

transfected with empty vector, IL-1 stimulated induction 4.1-fold
over the control. Runx-2 transfection increased basal levels
2.1-fold and, together, IL-1 and Runx-2 synergistically
increased reporter expression 9.6-fold (Fig. 6B). Treatment
with 10 µM SB203580 blocked synergism between Runx-2
and IL-1, demonstrating that p38 MAPK is required for this
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Figure 7. Mutational analysis of the MMP-13 promoter using stable integrants. Pooled stable cell lines were created by transfection with the reporter constructs
indicated followed by 1 month of weekly passages and selection in G418. Cells were plated at 2 × 105 per well in 6-well plates and treated with 10 ng/ml IL-1 in
serum-free medium for 24 h. All treatments were done in triplicate; cells were harvested and assayed for luciferase activity. Luciferase activity is shown as RLU;
error bars represent standard deviations. Values indicate fold IL-1 induction over basal expression for each construct.

effect. These experiments demonstrate that IL-1-induced p38
MAPK signaling synergizes with Runx-2 to activate MMP-13
transcription.
Mutational analysis of the stably transfected MMP-13
promoter
Finally, to further define the cis-acting sequences required for
IL-1 induction of MMP-13 transcription, we created single
mutants of the proximal AP-1 site and the Runx site and a
double mutant in the context of 405 bp of MMP-13 5′-flanking
DNA in pGL3. Pooled stable clones were created by co-transfection followed by selection in G418 for 1 month. IL-1 treatment of cells stably transfected with 405 bp of promoter
resulted in 4-fold IL-1 induction (Fig. 7). Clones containing a
mutation in the AP-1 site exhibited an 18-fold reduction in
both basal expression and IL-1 induction, while clones
containing a mutated Runx site showed 12-fold reduced basal
and IL-1 induction. Mutation of both sites caused a 46-fold
reduction in basal and IL-1-induced reporter expression. In
summary, mutation of each site dramatically reduced both
basal and IL-1-induced expression without substantially
altering the fold induction over control. Double mutation
caused a synergistic decrease in basal and IL-1-induced
reporter activity, implying that the AP-1 and Runx proteins
interact at the promoter. However, the double mutant remained
3.2-fold inducible in response to IL-1, suggesting that other IL-1responsive sites remain and that these sites can drive lower
levels of transcription.
DISCUSSION
We determined that Runx-2 participates in IL-1 induction of
MMP-13 in chondrocytic cells. We found that Runx-2 mRNA

and protein were high in untreated and IL-1-treated SW-1353
cells, which produce MMP-13, and much lower in RFs and
HFFs, which produce little or no MMP-13, respectively.
Therefore, the ability of a cell type to produce MMP-13 in
response to IL-1 correlated with Runx-2 expression, implying
that Runx-2 may participate in MMP-13 regulation in a tissuespecific manner (Fig. 8). Indeed, transfection of a plasmid
expressing the full-length Runx-2 protein augmented IL-1
induction of the endogenous MMP-13 gene while transfection
of the transactivation-deficient runt domain specifically
blocked IL-1 induction of the endogenous MMP-13 gene,
showing that this protein is required for gene expression.
Recent evidence suggesting that Runx-2 is a target of the
ERK MAPK pathway (23) and our data demonstrating the
importance of MAPK pathways for MMP-13 regulation
prompted us to hypothesize that IL-1 treatment resulted in p38
MAPK and/or JNK modulation of Runx-2 activity. Additional
data showing that protein kinase A (PKA) was required for
parathyroid hormone induction of rat MMP-13 and that PKA
could phosphorylate Runx-2 in vitro also demonstrate that
Runx-2 is a possible target for a kinase (29,30). We indirectly
tested this model by measuring the ability of transiently transfected upstream MAPK activators to activate MMP-13 transcription through Runx-2. Transfection of both ∆MEKK1 (an
activator of p38 MAPK, ERK and JNK) and MKK3 (an activator of p38 MAPK) synergistically activated the MMP-13
promoter when co-transfected with Runx-2. This effect was not
seen with the MMP-1 promoter, demonstrating the specificity of
Runx-2 for MMP-13 over MMP-1. These results parallel analysis of parathyroid hormone regulation of the rat MMP-13
promoter using the UMR rat osteosarcoma cell line (30) and
the demonstration that transfection of rat osteosarcoma cells
with Runx-2 augmented TGF-β induction of the endogenous
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Figure 8. IL-1 signaling to AP-1 and Runx-2 at the MMP-13 promoter. The model depicts the expression levels and roles of Runx and AP-1 proteins at the MMP-13
promoter in SW-1353 human chondrosarcoma cells and HFFs human foreskin fibroblasts. Arrows denote activation of signaling pathways or transcriptional activation at the MMP-13 promoter. The question mark refers to unidentified IL-1-responsive elements.

MMP-13 gene (24). Additionally, expression of Runx-2 in cell
lines stably transfected with the MMP-13 promoter synergistically activated reporter activity with IL-1 treatment, illustrating that IL-1 can signal through Runx-2 to activate gene
expression. Finally, mutation of the Runx site decreased
overall transcription from an integrated reporter construct,
demonstrating that this site participates in the regulation of
MMP-13 gene expression. Mutation of both the AP-1 site and
the Runx-2 site caused a synergistic reduction in transcription,
suggesting that transcription factors bound to these two sites
may interact (Fig. 8). Perhaps IL-1-induced p38 and JNK
directly phosphorylate Runx-2, leading to coactivator recruitment and an increase in transcription. Alternatively, Runx-2
may interact with AP-1 proteins directly or indirectly through
other factors after the phosphorylation of AP-1 by these
kinases. Indeed, direct interaction between Runx-2 and the AP-1
proteins c-Fos and c-Jun was recently demonstrated both
in vivo and in vitro (31).
We determined that transient transfections of MMP-13
5′-flanking DNA linked to a luciferase reporter gene did not
recapitulate the transcriptional induction of the endogenous
MMP-13 gene in response to IL-1. Other reporter constructs
like MMP-1–pGL3 and NF-κB–luciferase were IL-1 responsive. In contrast, 405 bp or 8 kb of stably transfected promoter
was IL-1 inducible, suggesting that 405 bp is sufficient for IL-1
induction. The 405 bp construct contains a continuous region
of high homology among mouse, human and rabbit promoters
with conserved AP-1, Ets and Runx transcription factorbinding sites (Fig. 1). When compared to the endogenous gene,
the same pattern of reporter gene inhibition by small molecule

MAPK inhibitors was seen with the 405 bp stable transfectants,
verifying that the reporter gene requires the same pathways as
the endogenous gene for IL-1 induction (9). Mutational
analysis revealed that both the AP-1 site and the Runx-binding
site are required for basal and IL-1-induced MMP-13 transcription.
The failure of transiently transfected DNA to respond to IL-1
has at least two possible explanations. The first is that limiting
amounts of transcription factors or other proteins involved in
IL-1 signaling are available in the nucleus. In a transiently
transfected cell, the number of reporter gene copies may
exceed the available pool of transcription factors and the
endogenous gene may be preferentially bound or targeted by
these factors after IL-1 treatment. In contrast, a stable line may
contain fewer copies of the promoter–reporter construct, thus
the available pool of factors is not exceeded. This model could
explain the inhibition of reporter activity after IL-1 treatment
of transiently transfected cells. Although we attempted to
rescue IL-1 induction in transient transfections by co-transfecting an expression plasmid for Runx-2, this approach did
not restore IL-1 induction (data not shown). A second explanation is that chromatin structure is required for regulation of
MMP-13. Chromosomally integrated DNA may organize
histones and other chromatin-associated proteins, thereby
repressing transcription in the absence of a stimulus. If this
were the case, transient transfection may result in high basal
reporter expression because unintegrated plasmid cannot
assume a native repressed chromatin structure and cannot
respond appropriately to IL-1.
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The structure of transiently transfected DNA has been
analyzed with conflicting results. Nucleosomal ladders of transiently transfected DNA were found by one group to have
repeat lengths similar to cellular chromatin (187 ± 5 bp), while
others have demonstrated spacings of 199 or 280 bp or a
complete lack of regular nucleosomes, respectively (reviewed
in 32). The latter results demonstrate that transiently transfected DNA may be more unwound and, therefore, more accessible to transcription factors and less appropriately regulated
compared to stably integrated reporter constructs.
There may be a direct link between regulation of chromatin
structure and the activities of Runx-2 protein. Recent evidence
indicates that Runx-2 protein is targeted to and interacts with
the nuclear matrix and that this ability is required for proper
functioning of the protein (33,34). Additionally, another
member of the Runx family, Runx-1, interacts with coactivators like the histone acetylase p300 through domains conserved
in Runx-2 protein (35). These putative Runx-2 properties may
be involved in IL-1 regulation of MMP-13 transcription.
When compared to other IL-1-inducible MMPs, MMP-13
has a more restricted expression pattern and requires a unique
set of signaling pathways and transcription factors that lead to
tissue-specific expression in chondrocytes. Our studies suggest
that both the AP-1 and the tissue-restricted Runx-2 transcription factors are important targets of IL-1-induced p38 MAPK
leading to MMP-13 transcription. Future studies directed
towards defining the direct downstream targets of the p38
MAPK and JNK pathways and studies identifying additional
proteins that activate polymerase II transcription of MMP-13
are needed to understand the molecular mechanism driving
gene expression. Understanding the mechanism of gene regulation may uncover new targets for the inhibition of MMP-13
expression in arthritis.
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